Switching on chromosomal translocations

Cancer Research

Volumn 66, Issue 16, 2006, Pages 7837-7839

  Ramiro, Almudena R ^a   Nussenzweig, Michel C ^b,c   Nussenzweig, André ^d  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b ROCKEFELLER UNIVERSITY   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED DEAMINASE; DEAMINASE; DNA; IMMUNOGLOBULIN HEAVY CHAIN; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER GENETICS; CHROMOSOME TRANSLOCATION; DNA DAMAGE; ENZYME ACTIVATION; GENE CONVERSION; GENE SWITCHING; GENETIC RECOMBINATION; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; REVIEW; SOMATIC HYPERMUTATION;

CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LYMPHOMA, B-CELL; MUTATION; NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 33748033705     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0863     Document Type: Review

References (16)

1. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005;5:251-62.
2. Chaudhuri J, Alt FW. Class-switch recombination: interplay of transcription, DNA deamination and DNA repair. Nat Rev Immunol 2004;4:541-52.
3. Muramatsu M, Sankaranand VS, Anant S, et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem 1999;274:18470-6.
4. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme [comment]. Cell 2000;102:553-63.
5. Revy P, Muto T, Levy Y, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2) [comment]. Cell 2000;102:565-75.
6. Rada C, Di Noia JM, Neuberger MS. Mismatch recognition and uracil excision provide complementary paths to both Ig switching and the A/T-focused phase of somatic mutation. Mol Cell 2004;16:163-71.
7. Kovalchuk AL, Kim JS, Park SS, et al. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci U S A 2002;99:1509-14.
8. Ramiro AR, Jankovic M, Eisenreich T, et ai. AID is required for c-myc/IgH chromosome translocations in vivo. Cell 2004;118:431-8.
9. Unniraman S, Zhou S, Schatz DG. Identification of an AID-independent pathway for chromosomal translocations between the IgH switch region and Myc. Nat Immunol 2004;5:1117-23.
10. Ramiro AR, Jankovic M, Callen E, et al. Role of genomic instability and p53 in AID-induced c-myc-IgH translocations. Nature 2006;440:105-9.
11. Fernandez-Capetillo O, Lee A, Nussenzweig M, Nussenzweig A. H2AX: the histone guardian of the genome. DNA Repair (Amst) 2004;3:959-67.
12. Franco S, Gostissa M, Zha S, et al. H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Mol Cell 2006;21:201-14.
13. Bassing CH, Suh H, Ferguson DO, et al. Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell 2003;114:359-70.
14. Ward I, Difilippantonio S, Minn K, et al. 53BP1 cooperates with p53 and functions as a haploinsufficient tumor suppressor in mice. Mol Cell Biol 2005;22: 10079-86.
15. Phan RT, Dalla-Favera H. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004;432:635-9.
16. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001;412:341-6.